CD8A and melanoma: Using deconvolution-based analysis, Riaz et al. reported that melanoma patients treated with the PD-1 inhibitor nivolumab exhibited higher baseline CD8+ T-cell infiltration and demonstrated enhanced immune activation following treatment [50].